These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
172 related articles for article (PubMed ID: 20858016)
1. Proteomic identification of paclitaxel-resistance associated hnRNP A2 and GDI 2 proteins in human ovarian cancer cells. Lee DH; Chung K; Song JA; Kim TH; Kang H; Huh JH; Jung SG; Ko JJ; An HJ J Proteome Res; 2010 Nov; 9(11):5668-76. PubMed ID: 20858016 [TBL] [Abstract][Full Text] [Related]
2. Identification of platinum-resistance associated proteins through proteomic analysis of human ovarian cancer cells and their platinum-resistant sublines. Yan XD; Pan LY; Yuan Y; Lang JH; Mao N J Proteome Res; 2007 Feb; 6(2):772-80. PubMed ID: 17269733 [TBL] [Abstract][Full Text] [Related]
3. [Proteomic analysis of human ovarian cancer cell lines and their platinum-resistant clones]. Yan XD; Pan LY Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):584-7. PubMed ID: 17181965 [TBL] [Abstract][Full Text] [Related]
4. Mitochondrial comparative proteomics of human ovarian cancer cells and their platinum-resistant sublines. Dai Z; Yin J; He H; Li W; Hou C; Qian X; Mao N; Pan L Proteomics; 2010 Nov; 10(21):3789-99. PubMed ID: 20957754 [TBL] [Abstract][Full Text] [Related]
5. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Chuthapisith S; Layfield R; Kerr ID; Hughes C; Eremin O Int J Oncol; 2007 Jun; 30(6):1545-51. PubMed ID: 17487377 [TBL] [Abstract][Full Text] [Related]
6. Weakened spindle checkpoint with reduced BubR1 expression in paclitaxel-resistant ovarian carcinoma cell line SKOV3-TR30. Fu Y; Ye D; Chen H; Lu W; Ye F; Xie X Gynecol Oncol; 2007 Apr; 105(1):66-73. PubMed ID: 17234259 [TBL] [Abstract][Full Text] [Related]
7. Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells. Kim SH; Juhnn YS; Song YS Ann N Y Acad Sci; 2007 Jan; 1095():82-9. PubMed ID: 17404021 [TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of human ovarian cancer paclitaxel-resistant cell lines. Cao L; Li X; Zhang Y; Peng F; Yi H; Xu Y; Li X; Wang Q Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Apr; 35(4):286-94. PubMed ID: 20448348 [TBL] [Abstract][Full Text] [Related]
9. Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Yan XD; Li M; Yuan Y; Mao N; Pan LY Oncol Rep; 2007 May; 17(5):1163-9. PubMed ID: 17390060 [TBL] [Abstract][Full Text] [Related]
10. Quantitative proteomic analysis of mitochondria from human ovarian cancer cells and their paclitaxel-resistant sublines. Chen M; Huang H; He H; Ying W; Liu X; Dai Z; Yin J; Mao N; Qian X; Pan L Cancer Sci; 2015 Aug; 106(8):1075-83. PubMed ID: 26033570 [TBL] [Abstract][Full Text] [Related]
11. A proteomic kinetic analysis of IGROV1 ovarian carcinoma cell line response to cisplatin treatment. Le Moguen K; Lincet H; Marcelo P; Lemoisson E; Heutte N; Duval M; Poulain L; Vinh J; Gauduchon P; Baudin B Proteomics; 2007 Nov; 7(22):4090-101. PubMed ID: 17994630 [TBL] [Abstract][Full Text] [Related]
12. Glycoproteomics of paclitaxel resistance in human epithelial ovarian cancer cell lines: towards the identification of putative biomarkers. Di Michele M; Marcone S; Cicchillitti L; Della Corte A; Ferlini C; Scambia G; Donati MB; Rotilio D J Proteomics; 2010 Mar; 73(5):879-98. PubMed ID: 19951750 [TBL] [Abstract][Full Text] [Related]
13. Comparative proteomic analysis of cisplatin sensitive IGROV1 ovarian carcinoma cell line and its resistant counterpart IGROV1-R10. Le Moguen K; Lincet H; Deslandes E; Hubert-Roux M; Lange C; Poulain L; Gauduchon P; Baudin B Proteomics; 2006 Oct; 6(19):5183-92. PubMed ID: 16941573 [TBL] [Abstract][Full Text] [Related]
14. Low expression of S100P associated with paclitaxel resistance in ovarian cancer cell line. Gao JH; He ZJ; Wang Q; Li X; Li YX; Liu M; Zheng JH; Tang H Chin Med J (Engl); 2008 Aug; 121(16):1563-8. PubMed ID: 18982869 [TBL] [Abstract][Full Text] [Related]
15. Cross-resistance to the synthetic retinoid CD437 in a paclitaxel-resistant human ovarian carcinoma cell line is independent of the overexpression of retinoic acid receptor-gamma. Kumar A; Soprano DR; Parekh HK Cancer Res; 2001 Oct; 61(20):7552-5. PubMed ID: 11606393 [TBL] [Abstract][Full Text] [Related]
16. Proteomic tracking of serum protein isoforms as screening biomarkers of ovarian cancer. Ahmed N; Oliva KT; Barker G; Hoffmann P; Reeve S; Smith IA; Quinn MA; Rice GE Proteomics; 2005 Nov; 5(17):4625-36. PubMed ID: 16220531 [TBL] [Abstract][Full Text] [Related]
17. Molecular description of evolving paclitaxel resistance in the SKOV-3 human ovarian carcinoma cell line. Lamendola DE; Duan Z; Yusuf RZ; Seiden MV Cancer Res; 2003 May; 63(9):2200-5. PubMed ID: 12727840 [TBL] [Abstract][Full Text] [Related]
18. Role of microRNAs in drug-resistant ovarian cancer cells. Sorrentino A; Liu CG; Addario A; Peschle C; Scambia G; Ferlini C Gynecol Oncol; 2008 Dec; 111(3):478-86. PubMed ID: 18823650 [TBL] [Abstract][Full Text] [Related]
19. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells. Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757 [TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers. Goto T; Takano M; Sakamoto M; Kondo A; Hirata J; Kita T; Tsuda H; Tenjin Y; Kikuchi Y Oncol Rep; 2006 May; 15(5):1265-71. PubMed ID: 16596196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]